Hemostemix Inc. — Investor Relations & Filings
Filings indexed
576
across all filing types
Latest filing
2022-03-03
Regulatory Filings
Country
CA
Canada
Listing
TSXV
HEM
Hemostemix Inc. is a clinical-stage biotechnology company specializing in regenerative medicine through the development and commercialization of autologous (patient's own) blood-derived stem cell therapies. The company's lead investigational product is ACP-01 (Angiogenic Precursor Cell treatment), a platform targeting ischemic conditions such as Critical Limb Ischemia (CLI), ischemic cardiomyopathy, and angina. ACP-01 is designed to address unmet medical needs, particularly in patients ineligible for standard revascularization procedures. Phase II clinical data re-examination for "no option" CLI indicated that ACP-01 administration was safe and associated with reduced ulcer size and decreased rates of amputation and death.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Report of exempt distribution excluding schedule 1 of Form 5.pdf | 2022-03-03 | English | |
| Material change report - English.pdf | 2022-03-02 | English | |
| News release - English.pdf | 2022-03-02 | English | |
| News release - English.pdf | 2022-03-02 | English | |
| News release - English.pdf | 2022-03-01 | English | |
| News release - English.pdf | 2022-02-03 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2022
8 filings
| |||||
| 47231608 | Report of exempt distribution excluding schedule 1 of Form 5.pdf | 2022-03-03 | English | ||
| 47231612 | Material change report - English.pdf | 2022-03-02 | English | ||
| 47231625 | News release - English.pdf | 2022-03-02 | English | ||
| 47231629 | News release - English.pdf | 2022-03-02 | English | ||
| 47231633 | News release - English.pdf | 2022-03-01 | English | ||
| 13561098 | News release - English.pdf | 2022-02-03 | English | ||
| 47231640 | News release - English.pdf | 2022-01-21 | English | ||
| 47231644 | News release - English.pdf | 2022-01-11 | English | ||
|
2021
7 filings
| |||||
| 22872967 | News release - English.pdf | 2021-12-09 | English | ||
| 47231657 | 52-109FV2 - Certification of interim filings - CFO (E).pdf | 2021-11-29 | English | ||
| 47231661 | Interim MD&A - English.pdf | 2021-11-29 | English | ||
| 47231697 | Interim financial statements/report – English.pdf | 2021-11-29 | English | ||
| 47231867 | News release - English.pdf | 2021-10-28 | English | ||
| 22294070 | News release - English.pdf | 2021-10-19 | English | ||
| 47231872 | News release - English.pdf | 2021-10-14 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
Hemostemix Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/47247/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=47247 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=47247 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=47247 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 47247}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Hemostemix Inc. (id: 47247)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.